share to facebook share to twitter share to linkedin email article FDA authorized another monoclonal antibody, sotrovimab, for emergency use in COVID-19 patients at high risk of severe disease, the agency announced on Wednesday.
Sotrovimab received emergency use authorization (EUA) for patients 12 years and older with mild to moderate COVID-19, who tested positive for SARS-CoV-2 and are at risk of progression to hospitalization or death. It is not authorized for hospitalized patients, especially patients requiring supplemental oxygen or mechanical ventilation, as it may worsen clinical outcomes in this population, the FDA said.FDA Allows New Antibody in Less-Severe COVID-19 | MedPage Today
Nothing but ‘experimental’ drugs and medical injected products, at a very high cost and NO BID PROFITS.
This is criminal behavior, when there are much safer remedies available at a very low cost, but the FDA, CDC, and WHO all deny this basic fact.